Auteur B. LARANCE

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

L. DEGENHARDT ; B. CLARK ; G. MACPHERSON ; O. LEPPAN ; S. NIELSEN ; E. ZAHRA ; B. LARANCE ; J. KIMBER ; D. MARTINO-BURKE ; M. HICKMAN ; M. FARRELL | 2023
Dans Lancet Psychiatry (The) (Vol.10, n°6, June 2023) Article : Périodique

Background: Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and buprenorphine are [...]

Plus d'info

Ajouter à la sélection

Lien externe

Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours

B. LARANCE ; L. DEGENHARDT ; N. LINTZERIS ; A. WINSTOCK ; R. MATTICK | 2011
Dans Drug and Alcohol Review (Vol.30, n°3, May 2011) Article : Périodique

AIMS: This paper (i) reviews the language used to describe and manage those patient practices that fall outside standard medical models of opioid treatment (for pain and opioid dependence), and (ii) proposes a consistent terminology that can be [...]

Plus d'info

Ajouter à la sélection

Measuring recovery among people who have completed residential rehabilitation: Factor structure and scoring of the substance use recovery evaluator

E. L. HATTON ; P. J. KELLY ; R. BRUNO ; J. NEALE ; B. LARANCE | 2025
Dans Drug and Alcohol Review (Vol.44, n°4, May 2025) Article : Périodique

INTRODUCTION: The substance use recovery evaluator (SURE) is a new patient-reported outcome measure of recovery from alcohol and other drugs. The original SURE validation study did not include clients from residential rehabilitation treatment, a[...]

Plus d'info

Ajouter à la sélection

Lien externe

Opioid agonist treatment for people who are dependent on pharmaceutical opioids (Review)

S. NIELSEN ; W. C. TSE ; B. LARANCE | 2022
Dans Cochrane Database of Systematic Reviews (n°9, 2022) Article : Périodique

Principaux messages : 1. La méthadone pourrait maintenir plus de personnes en traitement que la buprénorphine. 2. Les personnes ont rapporté consommer moins d'opioïdes avec la méthadone qu'avec la buprénorphine, bien que les analyses d'urine p[...]

Plus d'info

Ajouter à la sélection

Lien externe

Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce

B. OSBORNE ; B. LARANCE ; R. IVERS ; F. P. DEANE ; L. D. ROBINSON ; P. J. KELLY | 2022
Dans Drug and Alcohol Review (Vol.41, n°6, September 2022) Article : Périodique

ISSUES: Substance use disorders are associated with significant physical health comorbidities, necessitating an integrated treatment response. However, service fragmentation can preclude the management of physical health problems during addictio[...]

Plus d'info

Ajouter à la sélection

Lien externe

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia

D. HORYNIAK ; P. DIETZE ; B. LARANCE ; A. WINSTOCK ; L. DEGENHARDT | 2011
Dans International Journal of Drug Policy (Vol.22, n°2, March 2011) Article : Périodique

BACKGROUND Diversion and injection of buprenorphine (Subutex®) and buprenorphine-naloxone (Suboxone®) have been well documented. Recent international research and local anecdotal evidence suggest that these medications are also used by other rou[...]

Plus d'info

Ajouter à la sélection